Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:FENC NASDAQ:IMNM NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$32.04-3.5%$36.19$23.23▼$39.95$1.01B0.65366,423 shs422,367 shsFENCAdherex Technologies$8.57-8.1%$8.81$3.96▼$9.92$239.20M0.6496,574 shs58,179 shsIMNMImmunome$13.92-2.6%$10.52$5.15▼$15.13$1.21B1.942.06 million shs1.47 million shsRAPPRapport Therapeutics$26.50-0.9%$20.98$6.43▼$42.27$967.20M1.68720,346 shs519,118 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical0.00%-7.43%-17.97%-1.48%-14.70%FENCAdherex Technologies0.00%-13.26%-5.09%-2.39%+101.17%IMNMImmunome0.00%+12.44%+43.80%+61.11%+13.17%RAPPRapport Therapeutics0.00%-7.15%+14.22%+81.51%+35.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$32.04-3.5%$36.19$23.23▼$39.95$1.01B0.65366,423 shs422,367 shsFENCAdherex Technologies$8.57-8.1%$8.81$3.96▼$9.92$239.20M0.6496,574 shs58,179 shsIMNMImmunome$13.92-2.6%$10.52$5.15▼$15.13$1.21B1.942.06 million shs1.47 million shsRAPPRapport Therapeutics$26.50-0.9%$20.98$6.43▼$42.27$967.20M1.68720,346 shs519,118 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical0.00%-7.43%-17.97%-1.48%-14.70%FENCAdherex Technologies0.00%-13.26%-5.09%-2.39%+101.17%IMNMImmunome0.00%+12.44%+43.80%+61.11%+13.17%RAPPRapport Therapeutics0.00%-7.15%+14.22%+81.51%+35.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3332.13% UpsideFENCAdherex Technologies 2.67Moderate Buy$13.3355.58% UpsideIMNMImmunome 2.82Moderate Buy$23.2066.67% UpsideRAPPRapport Therapeutics 2.80Moderate Buy$35.3333.33% UpsideCurrent Analyst Ratings BreakdownLatest FENC, COLL, IMNM, and RAPP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025FENCAdherex TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMNMImmunomeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RAPPRapport TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025FENCAdherex TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMNMImmunomeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RAPPRapport TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025COLLCollegium PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/22/2025IMNMImmunomeThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.009/22/2025IMNMImmunomeThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.00(Data available from 10/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.60$12.32 per share2.60$7.10 per share4.51FENCAdherex Technologies$47.54M5.03$0.03 per share265.36($0.21) per share-40.81IMNMImmunome$9.04M134.03N/AN/A$2.27 per share6.13RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0430.815.32N/A5.13%97.28%13.87%11/6/2025 (Estimated)FENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)IMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)Latest FENC, COLL, IMNM, and RAPP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025COLLCollegium Pharmaceutical$1.89N/AN/AN/A$191.25 millionN/A11/6/2025Q3 2025FENCAdherex Technologies$0.16N/AN/AN/A$13.43 millionN/A11/6/2025Q3 2025RAPPRapport Therapeutics-$0.77N/AN/AN/AN/AN/A8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/7/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/A8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10FENCAdherex TechnologiesN/A4.854.59IMNMImmunomeN/A12.1312.13RAPPRapport TherapeuticsN/A22.7522.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AFENCAdherex Technologies55.51%IMNMImmunome44.58%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%FENCAdherex Technologies11.76%IMNMImmunome7.69%RAPPRapport Therapeutics13.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableFENCAdherex Technologies1027.91 million24.63 millionOptionableIMNMImmunome4087.04 million80.35 millionOptionableRAPPRapport TherapeuticsN/A36.50 million31.55 millionN/AFENC, COLL, IMNM, and RAPP HeadlinesRecent News About These CompaniesRapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by BrokeragesOctober 11 at 6:15 AM | marketbeat.comWeiss Ratings Reaffirms Sell (D-) Rating for Rapport Therapeutics (NASDAQ:RAPP)October 10 at 6:03 AM | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3% - What's Next?October 9 at 4:57 AM | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3% - Time to Buy?October 9 at 4:57 AM | marketbeat.comRapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body AnimationOctober 7, 2025 | businesswire.comWhy Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst OptimismOctober 2, 2025 | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 7.3% - Here's What HappenedOctober 2, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Time to Sell?October 1, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 4.3% Higher - Should You Buy?September 30, 2025 | marketbeat.comJMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study SuccessSeptember 30, 2025 | insidermonkey.comJMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study SuccessSeptember 30, 2025 | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 40,835 SharesSeptember 20, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Up 6.6% - Here's What HappenedSeptember 17, 2025 | marketbeat.comRapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TranscriptSeptember 17, 2025 | seekingalpha.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Recommendation of "Buy" by AnalystsSeptember 17, 2025 | marketbeat.comTruist Financial Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP)September 17, 2025 | marketbeat.comTruist Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Buy RecommendationSeptember 17, 2025 | msn.comRapport Therapeutics initiated with a Buy at TruistSeptember 16, 2025 | msn.comRapport assigned a new Buy at Truist on lead programSeptember 16, 2025 | msn.comRapport Therapeutics director buys $1.03M in common stockSeptember 15, 2025 | msn.comRapport Therapeutics director buys $1.03M in common stockSeptember 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?By Dan Schmidt | September 22, 2025Bassett Furniture: Buy Now, Sit Back, and Collect DividendsBy Thomas Hughes | October 11, 2025FENC, COLL, IMNM, and RAPP Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$32.04 -1.17 (-3.52%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$32.03 -0.01 (-0.03%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Adherex Technologies NASDAQ:FENC$8.57 -0.76 (-8.15%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$8.59 +0.02 (+0.23%) As of 10/10/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Immunome NASDAQ:IMNM$13.92 -0.37 (-2.59%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$14.12 +0.20 (+1.40%) As of 10/10/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Rapport Therapeutics NASDAQ:RAPP$26.50 -0.24 (-0.90%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$26.49 -0.01 (-0.04%) As of 10/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
